Skip to main content
. 2020 Jun 25;11(6):485. doi: 10.1038/s41419-020-2696-5

Fig. 3. Schematic summarizing the events and factors that are related to the limited effectiveness and spread of oncolytic viruses in GBM treatment.

Fig. 3

Oncolytic viruses that express immunomodulatory transgenes are administered to the host by systemic vascular delivery or orthotopic injection. Systemic injection of OVs can be neutralized by Abs and blocked by the blood–brain barrier, and the OVs administered by orthotopic injection are engulfed and destroyed by activated immune cells, limiting viral spread in GBM tissues. In addition, GSCs and Gb-MSCs in the tumor microenvironment may be resistant to viral infection, which decreases therapeutic efficacy.